ATE92107T1 - N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. - Google Patents

N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.

Info

Publication number
ATE92107T1
ATE92107T1 AT90304575T AT90304575T ATE92107T1 AT E92107 T1 ATE92107 T1 AT E92107T1 AT 90304575 T AT90304575 T AT 90304575T AT 90304575 T AT90304575 T AT 90304575T AT E92107 T1 ATE92107 T1 AT E92107T1
Authority
AT
Austria
Prior art keywords
fusion proteins
serum albumin
human serum
terminal fragments
containing fusion
Prior art date
Application number
AT90304575T
Other languages
English (en)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ATE92107T1 publication Critical patent/ATE92107T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT90304575T 1989-04-29 1989-04-26 N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. ATE92107T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898909919A GB8909919D0 (en) 1989-04-29 1989-04-29 Small polypeptides
EP90304575A EP0399666B1 (de) 1989-04-29 1990-04-26 N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen

Publications (1)

Publication Number Publication Date
ATE92107T1 true ATE92107T1 (de) 1993-08-15

Family

ID=10656003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90304575T ATE92107T1 (de) 1989-04-29 1989-04-26 N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.

Country Status (7)

Country Link
EP (2) EP0407008A3 (de)
AT (1) ATE92107T1 (de)
DE (1) DE69002395T2 (de)
DK (1) DK0399666T3 (de)
ES (1) ES2060033T3 (de)
GB (1) GB8909919D0 (de)
WO (1) WO1990013306A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
EP0428266B1 (de) * 1989-10-13 1994-09-28 Takara Shuzo Co. Ltd. Antikrebsmittel
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1322667A4 (de) * 2000-08-25 2004-08-18 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptoren 6-alpha und 6-beta
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
ES2437581T3 (es) 2005-11-17 2014-01-13 Zogenix, Inc. Suministro de formulaciones viscosas por inyección sin aguja
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2683791A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains & antagonists
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
JP2011518881A (ja) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EA026508B1 (ru) 2008-12-05 2017-04-28 Глэксо Груп Лимитед Единичный вариабельный домен иммуноглобулина и выделенный устойчивый к протеазе полипептид, связывающие сывороточный альбумин человека
BRPI1008014A2 (pt) 2009-02-19 2016-10-04 Glaxo Group Ltd domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
EP2453920A2 (de) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonisten, verwendung und verfahren zur teilweisen tnfr1-hemmung
ES2552177T3 (es) 2009-10-27 2015-11-26 Glaxo Group Limited Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
ES3050283T3 (en) 2010-07-09 2025-12-19 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP2605789B1 (de) 2010-08-17 2019-06-05 Ambrx, Inc. Modifizierte relaxinpolypeptide und ihre verwendungen
ME02637B (de) 2010-08-20 2017-06-20 Novartis Ag Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
MX2014000316A (es) 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
EP2851429B1 (de) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein und proteinkonjugate zur behandlung von diabetes und anwendungen davon
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
EP3068866B1 (de) 2013-11-16 2018-04-25 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
CA3176123A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
EP3914282A1 (de) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor von dux4 und verwendungen davon
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
EP3972993A1 (de) 2019-05-21 2022-03-30 Novartis AG Variante cd58-domänen und deren verwendungen
MX2022002638A (es) 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
WO2022204315A1 (en) 2021-03-23 2022-09-29 Terumo Bct, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4389762A1 (de) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitoren der dux4-aktivität und ihre therapeutische verwendung.
CN116574173A (zh) * 2023-06-25 2023-08-11 浙江诸暨聚源生物技术有限公司 蛋白稳定性增强的重组人源纤连蛋白突变体及其表达菌株

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989004172A1 (en) * 1987-11-09 1989-05-18 Chiron Ophthalmics Inc. Wound healing composition and method

Also Published As

Publication number Publication date
EP0399666A1 (de) 1990-11-28
EP0399666B1 (de) 1993-07-28
DE69002395D1 (de) 1993-09-02
ES2060033T3 (es) 1994-11-16
WO1990013306A2 (en) 1990-11-15
DE69002395T2 (de) 1993-11-25
DK0399666T3 (da) 1993-08-30
WO1990013306A3 (en) 1991-05-02
EP0407008A3 (en) 1991-07-17
GB8909919D0 (en) 1989-06-14
EP0407008A2 (de) 1991-01-09

Similar Documents

Publication Publication Date Title
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
ES2070919T3 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
DK0397420T3 (da) Enzymatisk fjernelse af en aminoterminal proteinsekvens
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
RU93045577A (ru) Слитные полипептиды
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
ATE111484T1 (de) Verbindungen zur verhinderung von thrombose.
NO923737L (no) Forbedret vevs-lim fremstilt ved anvendelse av kryopresipitat
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
ES2078229T3 (es) Procedimiento para la preparacion de un polipeptido similar a la motilina y su expresion.
DE69010750D1 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum
EP0326013A3 (de) Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time